EBR Systems Reports Substantial Doubt on Going Concern, Details 2025 Financing & Upcoming 1-for-10 Reverse Stock Split

summarizeSummary

EBR Systems, Inc. faces substantial doubt about its ability to continue as a going concern, despite raising $46.3 million in equity and beginning commercialization of its WiSE CRT System. The board has approved a 1-for-10 reverse stock split to be effected soon.

check_boxKey Events

• Substantial Doubt About Going Concern

  The company reported a net loss of $48.8 million and negative cash flows from operations of $53.2 million for 2025, with an accumulated deficit of $402.2 million, raising substantial doubt about its ability to continue as a going concern.

• Secured $46.3 Million in Equity Financing

  In May and June 2025, the company completed an institutional placement and a rights offering, raising a total of $46.3 million in net proceeds from the issuance of common stock.

• FDA Approval and Initial Commercialization

  The WiSE CRT System received FDA approval on April 11, 2025, leading to a commercial launch in Q2 2025 and generating $1.6 million in revenue from 33 trained physicians at 11 hospitals in 2025.

• Board Approves 1-for-10 Reverse Stock Split

  Following shareholder approval on March 11, 2026, the board approved a 1-for-10 reverse stock split, with the filing anticipated on March 27, 2026, to reclassify outstanding common stock.

auto_awesomeAnalysis

EBR Systems, Inc. has disclosed substantial doubt about its ability to continue as a going concern, citing recurring net losses and negative cash flows from operations. Despite this, the company successfully secured $46.3 million in equity financing during 2025, which provides a temporary lifeline. The company also reported initial commercialization of its WiSE CRT System following FDA approval in April 2025, generating minimal revenue of $1.6 million for the year. Additionally, stockholders approved a reverse stock split on March 11, 2026, with the board subsequently approving a 1-for-10 ratio, anticipated to be filed on March 27, 2026. This move is often aimed at increasing share price for exchange compliance or investor appeal, but can be viewed negatively by the market.